- TG Therapeutics press release (TGTX): Q4
- BRIUMVI U.S. net product revenue expected to be approximately $182 million and $594 million for the fourth quarter and full year of 2025, respectively
- Total global full year 2025 revenue of approximately $616 million
- Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results
2026 Financial Guidance
- Full Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million
- Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, and approximately $100 million in expenses associated with the subcutaneous BRIUMVI inventory build and secondary manufacturer start-up costs
TG Therapeutics reports Preliminary Q4 results
